Clinical trials of UFH - TrialResults-center.org

pathology

treatment

patient

Demonstrated benefit and harm

thrombosis prevention

enoxaparin

not classified

versus placebo or control

No demonstrated result for efficacy

meta-analysis

thrombosis prevention

UFH

not classified

versus placebo or control

No demonstrated result for efficacy

UFH inferior to placebo in terms of non fatala PE in Williams , 1978

meta-analysis

Trial	control	p<0.05	harm	NS
Williams , 1978	UFH vs placebo		non fatala PE 3.80 [1.47; 9.80]	fatal PE 0.00 [0.00; NaN]
Abraham-Inpijn , 1975	UFH vs placebo			non fatal bleeding NaN [NaN; NaN] fatal bleeding NaN [NaN; NaN] deep vein thrombosis 0.22 [0.03; 1.60] non fatala PE 0.00 [0.00; NaN] fatal PE NaN [NaN; NaN]
Lowe , 1981	UFH vs placebo	deep vein thrombosis 0.42 [0.19; 0.93]		non fatal bleeding 0.96 [0.14; 6.56] fatal bleeding NaN [NaN; NaN] non fatala PE 0.38 [0.08; 1.89] fatal PE NaN [NaN; NaN]
Morris, 1974	UFH vs no treatment	deep vein thrombosis 0.19 [0.06; 0.59]		non fatal bleeding 0.50 [0.05; 5.27] fatal bleeding NaN [NaN; NaN] non fatala PE NaN [NaN; NaN] fatal PE 0.00 [0.00; NaN]
Welin-Berger, 1982	UFH vs no treatment			non fatal bleeding ∞ [NaN; ∞] fatal bleeding NaN [NaN; NaN] deep vein thrombosis 1.33 [0.57; 3.14] non fatala PE NaN [NaN; NaN] fatal PE NaN [NaN; NaN]
Bergqvist , 1979	UFH vs no treatment	deep vein thrombosis 0.71 [0.52; 0.98]		non fatal bleeding NaN [NaN; NaN] fatal bleeding NaN [NaN; NaN] non fatala PE 1.38 [0.71; 2.67] fatal PE 0.00 [0.00; NaN]
Hampson, 1974	UFH vs placebo			non fatal bleeding NaN [NaN; NaN] fatal bleeding NaN [NaN; NaN] deep vein thrombosis 0.65 [0.39; 1.08] fatal PE NaN [NaN; NaN]
Moskovitz, 1978	UFH vs placebo	deep vein thrombosis 0.38 [0.20; 0.75]		non fatal bleeding ∞ [NaN; ∞] fatal bleeding NaN [NaN; NaN] non fatala PE 2.74 [0.30; 25.05] fatal PE NaN [NaN; NaN]
Gallus , 1973	UFH vs no treatment			deep vein thrombosis 0.38 [0.05; 2.92]
VTCSG, 1975	UFH vs no treatment			non fatal bleeding ∞ [NaN; ∞] fatal bleeding NaN [NaN; NaN] non fatala PE NaN [NaN; NaN] fatal PE NaN [NaN; NaN]
Mannucci , 1976	UFH vs no treatment	deep vein thrombosis 0.31 [0.10; 1.00]		non fatal bleeding 2.09 [0.42; 10.32] fatal bleeding NaN [NaN; NaN] non fatala PE NaN [NaN; NaN] fatal PE NaN [NaN; NaN]
Dechavanne, 1974	UFH vs no treatment	deep vein thrombosis 0.15 [0.04; 0.62]		non fatal bleeding 1.50 [0.27; 8.32] fatal bleeding NaN [NaN; NaN] non fatala PE ∞ [NaN; ∞] fatal PE 0.00 [0.00; NaN]
Dechavanne, 1975	UFH vs no treatment	deep vein thrombosis 0.13 [0.02; 0.96]		non fatal bleeding 0.00 [0.00; NaN] fatal bleeding NaN [NaN; NaN] non fatala PE NaN [NaN; NaN] fatal PE 0.00 [0.00; NaN]
Lahnborg, 1980	UFH vs placebo	deep vein thrombosis 0.53 [0.31; 0.90]		fatal bleeding NaN [NaN; NaN] non fatala PE ∞ [NaN; ∞] fatal PE NaN [NaN; NaN]
Xabregas , 1977	UFH vs placebo			non fatal bleeding 0.77 [0.23; 2.56] fatal bleeding NaN [NaN; NaN] deep vein thrombosis 0.00 [0.00; NaN] non fatala PE NaN [NaN; NaN] fatal PE NaN [NaN; NaN]
Bergqvist, 1979	UFH vs no treatment	deep vein thrombosis 0.65 [0.46; 0.91]		non fatal bleeding NaN [NaN; NaN] fatal bleeding NaN [NaN; NaN] non fatala PE NaN [NaN; NaN] fatal PE ∞ [NaN; ∞]
Galasko , 1976	UFH vs no treatment	deep vein thrombosis 0.36 [0.19; 0.69]		non fatal bleeding 0.00 [0.00; NaN] fatal bleeding NaN [NaN; NaN] non fatala PE NaN [NaN; NaN] fatal PE 0.40 [0.08; 1.97]
Moskovitz, 1978	UFH vs placebo			non fatal bleeding NaN [NaN; NaN] fatal bleeding NaN [NaN; NaN] deep vein thrombosis 0.99 [0.47; 2.10] non fatala PE ∞ [NaN; ∞] fatal PE 0.00 [0.00; NaN]
Svend-Hansen, 1981	UFH vs placebo	deep vein thrombosis 0.54 [0.32; 0.91]		fatal bleeding NaN [NaN; NaN] non fatala PE NaN [NaN; NaN] fatal PE 1.00 [0.06; 15.65]
Gallus , 1973	UFH vs no treatment	deep vein thrombosis 0.27 [0.09; 0.85]		fatal bleeding 0.50 [0.04; 6.55]
Morris , 1977	UFH vs no treatment			non fatal bleeding NaN [NaN; NaN] fatal bleeding NaN [NaN; NaN] deep vein thrombosis 0.75 [0.46; 1.22] non fatala PE NaN [NaN; NaN] fatal PE NaN [NaN; NaN]
	UFH vs no treatment
	UFH vs no treatment
	UFH vs placebo
	UFH vs placebo
	UFH vs placebo
	UFH vs placebo
	UFH vs placebo
	UFH vs placebo
	UFH vs placebo
	UFH vs placebo
	UFH vs placebo
	UFH vs placebo
	UFH vs placebo
	UFH vs placebo
	UFH vs placebo
	UFH vs placebo
	UFH vs placebo
	UFH vs placebo
	UFH vs no treatment
	UFH vs no treatment
	UFH vs no treatment
	UFH vs no treatment
	UFH vs no treatment
	UFH vs no treatment
	UFH vs no treatment
	UFH vs no treatment
	UFH vs no treatment
	UFH vs no treatment
	UFH vs no treatment
	UFH vs placebo
	UFH vs placebo
	UFH vs placebo
	UFH vs placebo
	UFH vs no treatment
	UFH vs no treatment
	UFH vs no treatment
	UFH vs no treatment
	UFH vs no treatment
	UFH vs no treatment
	UFH vs no treatment
	UFH vs no treatment
	UFH vs no treatment
	UFH vs placebo
	UFH vs no treatment
	UFH vs no treatment
	UFH vs no treatment
	UFH vs placebo
	UFH vs placebo
	UFH vs placebo

Trial	Treatments	Patients	Method
Williams , 1978	UFH twice daily for 14 days (n=106) vs. placebo (n=106)	elective orthopedic surgery	Sample size: 106/106 Primary endpoint: FU duration:
Abraham-Inpijn , 1975	UFH twice daily for 8 days (n=12) vs. placebo (n=13)	elective orthopedic surgery	Sample size: 12/13 Primary endpoint: FU duration:
Lowe , 1981	UFH twice daily for 16 days (n=51) vs. placebo (n=49)	elective orthopedic surgery	Sample size: 51/49 Primary endpoint: FU duration:
Morris, 1974	UFH twice daily for 10 days (n=36) vs. no treatment (n=36)	elective orthopedic surgery	Sample size: 36/36 Primary endpoint: FU duration:
Welin-Berger, 1982	UFH twice daily for 7 days (n=20) vs. no treatment (n=20)	elective orthopedic surgery	Sample size: 20/20 Primary endpoint: FU duration:
Bergqvist , 1979	UFH twice daily for 5 days (n=84) vs. no treatment (n=77)	elective orthopedic surgery	Sample size: 84/77 Primary endpoint: FU duration:
Hampson, 1974	UFH 3 times daily for 7- 10 days (n=48) vs. placebo (n=52)	elective orthopedic surgery	Sample size: 48/52 Primary endpoint: FU duration:
Moskovitz, 1978	UFH 3 times daily for 7 days (n=35) vs. placebo (n=32)	elective orthopedic surgery	Sample size: 35/32 Primary endpoint: FU duration:
Gallus , 1973	UFH twice daily for A days (n=8) vs. no treatment (n=9)	elective orthopedic surgery	Sample size: 8/9 Primary endpoint: FU duration:
VTCSG, 1975	UFH twice daily for 10 days (n=34) vs. no treatment (n=30)	elective orthopedic surgery	Sample size: 34/30 Primary endpoint: FU duration:
Mannucci , 1976	UFH 3 times daily for 7 days (n=23) vs. no treatment (n=24)	elective orthopedic surgery	Sample size: 23/24 Primary endpoint: FU duration:
Dechavanne, 1974	UFH 3 times daily for 10 days (n=29) vs. no treatment (n=29)	elective orthopedic surgery	Sample size: 29/29 Primary endpoint: FU duration:
Dechavanne, 1975	UFH 3 times daily for 10 days (n=20) vs. no treatment (n=21)	elective orthopedic surgery	Sample size: 20/21 Primary endpoint: FU duration:
Lahnborg, 1980	UFH twice daily for 10 days (n=70) vs. placebo (n=69)	traumatic orthopedic surgery	Sample size: 70/69 Primary endpoint: FU duration:
Xabregas , 1977	UFH twice daily for 14 days (n=27) vs. placebo (n=26)	traumatic orthopedic surgery	Sample size: 27/26 Primary endpoint: FU duration:
Bergqvist, 1979	UFH twice daily for 5 days (n=32) vs. no treatment (n=23)	traumatic orthopedic surgery	Sample size: 32/23 Primary endpoint: FU duration:
Galasko , 1976	UFH twice daily (duration unknown) (n=50) vs. no treatment (n=50)	traumatic orthopedic surgery	Sample size: 50/50 Primary endpoint: FU duration:
Moskovitz, 1978	UFH 3 times daily for 7 days (n=29) vs. placebo (n=23)	traumatic orthopedic surgery	Sample size: 29/23 Primary endpoint: FU duration:
Svend-Hansen, 1981	UFH 3 times daily for 14 days (n=65) vs. placebo (n=65)	traumatic orthopedic surgery	Sample size: 65/65 Primary endpoint: FU duration:
Gallus , 1973	UFH 3 times daily for A (n=23) vs. no treatment (n=23)	traumatic orthopedic surgery	Sample size: 23/23 Primary endpoint: FU duration:
Morris , 1977	UFH 3 times daily for 10 days (n=24) vs. no treatment (n=24)	traumatic orthopedic surgery	Sample size: 24/24 Primary endpoint: FU duration:
Kakkar (IMT)	UFH 3 times daily for 7 days (n=2111) vs. no treatment (n=2137)	All other general surgery	Sample size: 2111/2137 Primary endpoint: FU duration:
Gruber	UFH 3 times daily for 7 days (n=119) vs. no treatment (n=113)	All other general surgery	Sample size: 119/113 Primary endpoint: FU duration:
Kakkar, 1972	UFH twice daily for 7 days (n=39) vs. placebo (n=39)	All other general surgery	Sample size: 39/39 Primary endpoint: FU duration:
Kiil, 1978	UFH twice daily for 7 days (n=650) vs. placebo (n=663)	All other general surgery	Sample size: 650/663 Primary endpoint: FU duration:
Torngren, 1978	UFH twice daily for 6-8 days (n=66) vs. placebo (n=62)	all other general surgery	Sample size: 66/62 Primary endpoint: FU duration:
Torngren	UFH twice daily for 6-8 days (n=47) vs. placebo (n=62)	all other general surgery	Sample size: 47/62 Primary endpoint: FU duration:
Lahnborg, 1975	UFH twice daily for 5 days (n=58) vs. placebo (n=54)	all other general surgery	Sample size: 58/54 Primary endpoint: FU duration:
Lahnborg, 1976	UFH twice daily for 5 days (n=24) vs. placebo (n=24)	all other general surgery	Sample size: 24/24 Primary endpoint: FU duration:
Covey, 1975	UFH twice daily for 8 days (n=53) vs. placebo (n=52)	all other general surgery	Sample size: 53/52 Primary endpoint: FU duration:
Belch, 1980	UFH twice daily for 7 days (n=24) vs. placebo (n=25)	all other general surgery	Sample size: 24/25 Primary endpoint: FU duration:
Taberner, 1978	UFH twice daily for 7 days (n=50) vs. placebo (n=50)	all other general surgery	Sample size: 50/50 Primary endpoint: FU duration:
Strand, 1975	UFH twice daily for 7 days (n=55) vs. placebo (n=55)	all other general surgery	Sample size: 55/55 Primary endpoint: FU duration:
Roberts, 1975	UFH twice daily for 7 days (n=39) vs. placebo (n=45)	all other general surgery	Sample size: 39/45 Primary endpoint: FU duration:
Ribaudo, 1975	UFH twice daily for A days (n=75) vs. placebo (n=75)	all other general surgery	Sample size: 75/75 Primary endpoint: FU duration:
Wu, 1977	UFH twice daily for 7 days (n=44) vs. placebo (n=44)	all other general surgery	Sample size: 44/44 Primary endpoint: FU duration:
Lawrence, 1977	UFH twice daily for 5 days (n=133) vs. placebo (n=129)	all other general surgery	Sample size: 133/129 Primary endpoint: FU duration:
Muiticentre, 1984	UFH twice daily for 5-7 days (n=222) vs. placebo (n=108)	all other general surgery	Sample size: 222/108 Primary endpoint: FU duration:
Jourdan, 1984	UFH twice daily for 5 days (n=21) vs. placebo (n=21)	all other general surgery	Sample size: 21/21 Primary endpoint: FU duration:
Gordon-Smith, 1972	UFH twice daily for 5 days (n=-9) vs. no treatment (n=51)	all other general surgery	Sample size: -9/51 Primary endpoint: FU duration:
Nicolaides, 1972	UFH twice daily for 7 days (n=128) vs. no treatment (n=122)	all other general surgery	Sample size: 128/122 Primary endpoint: FU duration:
Multiunit, 1974	UFH twice daily for 7 days (n=128) vs. no treatment (n=128)	all other general surgery	Sample size: 128/128 Primary endpoint: FU duration:
Abernethy, 1974	UFH twice daily for 7 days (n=63) vs. no treatment (n=62)	all other general surgery	Sample size: 63/62 Primary endpoint: FU duration:
Clarke-Pearson, 1983	UFH twice daily for 7 days (n=95) vs. no treatment (n=105)	all other general surgery	Sample size: 95/105 Primary endpoint: FU duration:
Plante, 1979	UFH twice daily for 8 days (n=42) vs. no treatment (n=66)	all other general surgery	Sample size: 42/66 Primary endpoint: FU duration:
Abraham-Inpijn, 1979	UFH twice daily for 7 days (n=20) vs. no treatment (n=20)	all other general surgery	Sample size: 20/20 Primary endpoint: FU duration:
Spebar, 1981	UFH twice daily for 5-7 days (n=24) vs. no treatment (n=19)	all other general surgery	Sample size: 24/19 Primary endpoint: FU duration:
Sagar, 1974	UFH twice daily for 5 days (n=264) vs. no treatment (n=236)	all other general surgery	Sample size: 264/236 Primary endpoint: FU duration:
Koppenhagen, 1982	UFH twice daily (n=162) vs. no treatment (n=50)	all other general surgery	Sample size: 162/50 Primary endpoint: FU duration:
Bergqvist, 1980	UFH twice daily for 5 days (n=53) vs. no treatment (n=58)	all other general surgery	Sample size: 53/58 Primary endpoint: FU duration:
Torngren, 1978	UFH 3 times daily for 6-8 days (n=10) vs. placebo (n=10)	all other general surgery	Sample size: 10/10 Primary endpoint: FU duration:
Kruse-Blinkenberg, 1980	UFH 3 times daily for 8 days (n=29) vs. placebo (n=33)	all other general surgery	Sample size: 29/33 Primary endpoint: FU duration:
Kraytman, 1977	UFH 3 times daily for 6 days (n=25) vs. placebo (n=22)	all other general surgery	Sample size: 25/22 Primary endpoint: FU duration:
Marchetti, 1982	UFH 3 times daily (n=16) vs. placebo (n=13)	all other general surgery	Sample size: 16/13 Primary endpoint: FU duration:
Gallus, 1973	UFH 3 times daily for A (n=100) vs. no treatment (n=109)	all other general surgery	Sample size: 100/109 Primary endpoint: FU duration:
Gallus, 1976	UFH 3 times daily for 7 days (n=408) vs. no treatment (n=412)	all other general surgery	Sample size: 408/412 Primary endpoint: FU duration:
Groote Schuur, 1979	UFH 3 times daily for 6 days (n=323) vs. no treatment (n=323)	all other general surgery	Sample size: 323/323 Primary endpoint: FU duration:
Kraytman, 1976	UFH 3 times daily for 6 days (n=21) vs. no treatment (n=28)	all other general surgery	Sample size: 21/28 Primary endpoint: FU duration:
Kraytman, 1977	UFH 3 times daily for 6 days (n=23) vs. no treatment (n=27)	all other general surgery	Sample size: 23/27 Primary endpoint: FU duration:
Kettunen, 1974	UFH 3 times daily for 7 days (n=83) vs. no treatment (n=117)	all other general surgery	Sample size: 83/117 Primary endpoint: FU duration:
Caloghera, 1984	UFH 3 times daily for 7 days (n=40) vs. no treatment (n=40)	all other general surgery	Sample size: 40/40 Primary endpoint: FU duration:
Marchelli, 1983	UFH 3 times daily for ? (n=30) vs. no treatment (n=30)	all other general surgery	Sample size: 30/30 Primary endpoint: FU duration:
Ziemski, 1979	UFH 3 times daily for 2 days (n=30) vs. no treatment (n=20)	all other general surgery	Sample size: 30/20 Primary endpoint: FU duration:
Bejjani, 1983	UFH twice daily for 2 days (n=17) vs. placebo (n=17)	urologic surgery	Sample size: 17/17 Primary endpoint: FU duration:
Coe, 1978	UFH twice daily for D (n=28) vs. no treatment (n=24)	urologic surgery	Sample size: 28/24 Primary endpoint: FU duration:
Sebeseri, 1975	UFH twice daily for D (n=34) vs. no treatment (n=31)	urologic surgery	Sample size: 34/31 Primary endpoint: FU duration:
Allen, 1978	UFH twice daily for D (n=30) vs. no treatment (n=30)	urologic surgery	Sample size: 30/30 Primary endpoint: FU duration:
Hedlund, 1979	UFH 3 times daily for 5 days (n=30) vs. placebo (n=29)	urologic surgery	Sample size: 30/29 Primary endpoint: FU duration:
Kutnowski, 1977	UFH 3 times daily for 6 days (n=6) vs. placebo (n=13)	urologic surgery	Sample size: 6/13 Primary endpoint: FU duration:
Vandendris, 1980	UFH 3 times daily for 6 days (n=32) vs. placebo (n=33)	urologic surgery	Sample size: 32/33 Primary endpoint: FU duration:

thrombosis prevention

UFH

not classified

versus aspirin

No demonstrated result for efficacy

meta-analysis

thrombosis prevention

UFH

not classified

versus DHE

No demonstrated result for efficacy

meta-analysis

thrombosis prevention

UFH

not classified

versus oral anticoagulant

No demonstrated result for efficacy

meta-analysis

venous thrombosis

heparin

not classified

versus

No demonstrated result for efficacy

subcutaneous heparin inferior to intravenous heparin in terms of extension or recurrence of VTE in Hull, 1986

meta-analysis

Trial	control	p<0.05	harm	NS
Krahenbuhl, 1979	subcutaneous heparin vs intravenous heparin
Bentley, 1980	subcutaneous heparin vs intravenous heparin	extension or recurrence of VTE 0.10 [0.01; 0.75]		major hemorrhage 0.25 [0.03; 2.16]
Andersson, 1982	subcutaneous heparin vs intravenous heparin
Hull, 1986	subcutaneous heparin vs intravenous heparin		extension or recurrence of VTE 3.73 [1.10; 12.68]	major hemorrhage 1.02 [0.15; 6.98]
Doyle, 1987	subcutaneous heparin vs intravenous heparin			major hemorrhage 2.04 [0.39; 10.65] extension or recurrence of VTE 1.02 [0.31; 3.31]
Walker, 1987	subcutaneous heparin vs intravenous heparin	extension or recurrence of VTE 0.15 [0.04; 0.65]		major hemorrhage 1.00 [0.15; 6.82]
Lopaciuk	subcutaneous heparin vs intravenous heparin			major hemorrhage 1.92 [0.18; 20.43] extension or recurrence of VTE 0.27 [0.06; 1.25]
Pini, 1990	subcutaneous heparin vs intravenous heparin			major hemorrhage 0.54 [0.18; 1.56] extension or recurrence of VTE 1.93 [0.36; 10.35]

Trial	Treatments	Method
Krahenbuhl, 1979	subcutaneous sodic heparin 30 000 U daily (mean) (n=23) vs. intravenous sodic heparin 30 000 U daily (mean) (n=25)	Sample size: 23/25 Primary endpoint: FU duration:
Bentley, 1980	subcutaneous calcic heparin 37 000 U daily (mean) (n=50) vs. intravenous sodic heparin 36 800 U daily (mean) (n=50)	Sample size: 50/50 Primary endpoint: FU duration:
Andersson, 1982	subcutaneous sodic heparin 36 800 U daily (mean) (n=72) vs. intravenous sodic heparin 33 250 U daily (mean) (n=69)	Sample size: 72/69 Primary endpoint: FU duration:
Hull, 1986	subcutaneous sodic heparin 32 300 U daily (mean) (n=57) vs. intravenous sodic heparin 29 700 U daily (mean) (n=58)	Sample size: 57/58 Primary endpoint: FU duration:
Doyle, 1987	subcutaneous calcic heparin 29 200 U daily (mean) (n=51) vs. intravenous calcic heparin 29 600 U daily (mean) (n=52)	Sample size: 51/52 Primary endpoint: FU duration:
Walker, 1987	subcutaneous calcic heparin 29 375 U daily (mean) (n=50) vs. intravenous calcic heparin 24 384 U daily (mean) (n=50)	Sample size: 50/50 Primary endpoint: FU duration:
Lopaciuk	subcutaneous sodic heparin 34 400 U daily (mean) (n=48) vs. intravenous sodic heparin 37 000 U daily (mean) (n=46)	Sample size: 48/46 Primary endpoint: FU duration:
Pini, 1990	subcutaneous calcic heparin 33 800 U daily (mean) (n=138) vs. intravenous sodic heparin 31 700 U daily (mean) (n=133)	Sample size: 138/133 Primary endpoint: FU duration:

UFH Description Results NMA

Group by...

UFH
Description Results NMA